




which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement, except those identified above.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Heidi Sease Nebel", written over the typed name.

HEIDI SEASE NEBEL, Reg. No. 37,719  
McKEE, VOORHEES & SEASE, P.L.C.  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

- bja -

Attorneys of Record



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/617,943
		Filing Date	July 11, 2003
		First Named Inventor	WANG, Summing, et al.
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	P06341US00
Sheet	1	of	1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Shackelford, Rodney et al. "Desferrioxamine treatment increases the genomic stability of Ataxia-telangiectasia cells" ScienceDirect, DNA Repair, Vol 2, Issu 9, Sept. 2003, pp 971-981	
	2	Simpson, Marty "Buck Researcher Links Iron to Parkinson's Disease" Buck Institute, Neuron 3/26/2003	
	3	Polla, Ada S., et al. "Iron as the malignant spirit in successful ageing" Ageing Research Reviews 2(2003) 25-37	
	4	Young, Ian S., et al. "The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat" ScienceDirect, Free Radical Biology and Medicine, Vol. 18, Issue 5, May 1995, pp 833-840	
	5	Kaur, Deepinder et al. "Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo" Science Direct, Neuron, Vol. 37, Issue 6, 3/27/2003, pp 899-909	
	6	Wong, Alice PhD, et al. "Oxidative Stress in Friedreich's Ataxia: Mechanisms and Potential Therapy" Friedreich's ataxia (FRDA) NAF 1999	
	7	Naughton, D.P., "Iron(III)-mediated intra-articular crystal deposition in arthritis: a therapeutic role for iron chelators" ScienceDirect, Medical Hypotheses, Vol. 57, Issue 1, July 2001, pp. 120-122	
	8	Duffy, SJ, et al. "Iron chelation improves endothelial function in patients with coronary artery disease." Entrez-Pub-Med, Abstract June 12, 2001	
	9	Kuperstein, Faina et al., "Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity" Journal of Neurochemistry, Vol. 86, No. 1, 2003 114-125	
	10	Cameron, NE., et al. "Neurovascular dysfunction in diabetic rates. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents." ABSTRACT Entrez-PubMed, J. Clin. Invest. 1995 August;96(2); 1159-63	
	11	Buss, Joan L., et al. "The Role of Iron Chelation in Cancer Therapy" Abstract - Currently Medicinal Chemistry, Vol. 10, No. 12, 2003	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.